Cognition Therapeutics, Inc.
CGTX
$1.01
-$0.03-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.08% | 6.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.24% | -35.51% | |||
| Operating Income | 12.24% | 35.51% | |||
| Income Before Tax | 13.96% | -36.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.96% | -36.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.96% | -36.70% | |||
| EBIT | 12.24% | 35.51% | |||
| EBITDA | 12.24% | 35.52% | |||
| EPS Basic | 15.23% | -35.81% | |||
| Normalized Basic EPS | 15.31% | -35.59% | |||
| EPS Diluted | 15.23% | -35.81% | |||
| Normalized Diluted EPS | 15.31% | -35.59% | |||
| Average Basic Shares Outstanding | 1.61% | 0.66% | |||
| Average Diluted Shares Outstanding | 1.61% | 0.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||